Welcome to our dedicated page for Pasithea Therapeutics news (Ticker: ktta), a resource for investors and traders seeking the latest updates and insights on Pasithea Therapeutics stock.
Pasithea Therapeutics Corp. (symbol: KTTA) is a forward-thinking biotechnology company dedicated to the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders and other diseases, including RASopathies. By leveraging advancements in the fields of neuroscience, translational medicine, and drug development, Pasithea Therapeutics aims to address unmet medical needs and improve patient outcomes.
The company's robust pipeline includes promising treatments for Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. These conditions represent significant therapeutic challenges, and Pasithea Therapeutics is committed to advancing research to bring effective solutions to market.
Recent achievements highlight the company's progress in translating scientific discoveries into potential therapeutic applications. Notably, initial safety, tolerability, and biomarker data are expected to be reported in the second half of 2024. This milestone will be crucial in validating the efficacy of their treatments and guiding future development.
As a driver of innovation in biotechnology, Pasithea Therapeutics collaborates with leading researchers, healthcare providers, and institutions to enhance its research capabilities and expedite the drug development process. Strategic partnerships play a pivotal role in the company's ability to stay at the forefront of scientific advancements and bring new therapies to patients in need.
The financial condition of Pasithea Therapeutics is underscored by its commitment to transparency and robust corporate governance. The company continuously strives to maintain a solid financial foundation to support its research and development activities.
Stay updated with the latest news and developments from Pasithea Therapeutics by checking their regular press releases and corporate communications. For more information, please contact Patrick Gaynes, Corporate Communications, at pgaynes@pasithea.com.
Pasithea Therapeutics Corp. (KTTA) announced that Prof. Lawrence Steinman will deliver a keynote address at the AAAS Annual Meeting on March 4, 2023. Prof. Steinman's research linking the Epstein-Barr virus to multiple sclerosis (MS) was recognized as a runner-up for the 2022 Science Magazine Breakthrough of the Year.
The company's PAS-002 program aims to develop a DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS, providing potential treatment avenues for this chronic autoimmune disease affecting 2.8 million worldwide.
Pasithea Therapeutics Corp. announced that Lawrence Steinman, Chairman, will deliver a significant lecture at the ACTRIMS Forum in San Diego on February 23, 2023. The event, themed “MS: Going Viral,” focuses on the role of the Epstein-Barr virus in Multiple Sclerosis (MS), which relates to the Company's PAS-002 drug discovery program. PAS-002 aims to create an engineered DNA plasmid vaccine targeting GlialCAM, a protein implicated in MS. MS affects 2.8 million people globally, with relapsing remitting MS being the most common type. Steinman's research was recognized as a runner-up for Science Magazine’s 2022 Breakthrough of the Year.
FAQ
What is the current stock price of Pasithea Therapeutics (ktta)?
What is the market cap of Pasithea Therapeutics (ktta)?
What does Pasithea Therapeutics Corp. specialize in?
What diseases are included in Pasithea Therapeutics' pipeline?
When is the initial safety and biomarker data expected to be reported?
Who can be contacted for more information about Pasithea Therapeutics?
How does Pasithea Therapeutics advance its research?
What is the significance of Pasithea Therapeutics' work?
Does Pasithea Therapeutics provide regular updates?
What are the core areas of research for Pasithea Therapeutics?
What are RASopathies?
How does Pasithea Therapeutics support its financial stability?
